Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Minimum wage a public health issue?

Some states, and perhaps soon the federal government, are considering increasing the minimum wage. President Joe Biden voiced his support for raising the federal minimum wage to $15 per hour while on the campaign trail, and also included it in his recent economic stimulus package. A ballot initiative in Florida to raise the statewide minimum by 2026 passed in November 2020. While discussions around raising the minimum wage typically center on the economic benefits and potential labor force impacts that would affect low-wage workers, there are also population health benefits to consider. These range from better physical and mental health outcomes to indirect influences on individual behaviors that affect health—but the existing research is limited at best. However, what we do know suggests that raising the minimum wage may not be uniformly helpful. Should policy makers pursue raising the minimum wage, it will be key to do so in a way that does not exacerbate long-standing inequities in both income and health.

 

Source: JAMA

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!